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There has been increasing discussion in the econom ic lit erature, about  the 
appropriateness of using general populat ion values within technology appraisal.  
This paper proposes an alternat ive approach to incorporat ing pat ient  values into 
the cost -effect iveness decision rule that  lies at  the heart  of funding decisions.  
Whilst  the current  decision rule is const ructed around a technical quest ion, 
nam ely, ‘which t reatm ent  is the m ost cost -effect ive?’, the key policy quest ion is 
‘which t reatm ents should be offered to the pat ient?’.  A two-part  decision rule is 
explored which gives the pat ient  the choice of the m ost  cost -effect ive t reatment  
plus all cheaper opt ions.  Whilst  the adopt ion of this pat ient -based cost -
effect iveness rule m ay not  alter m any decisions com pared to the current  
approach, it  would represent  a profound shift  in the way that  pat ient  values and 







Purchasers of health care across the world increasingly m ake decisions about  
which t reatments can be used by pat ients using cost -effect iveness considerat ions.  
Within this fram ework, effect iveness is m ost  frequent ly m easured using qualit y-
adjusted life years (QALYs) .  QALYs are calculated by sum ming m orbidit y 
weighted life-expectancy, with the weights typically based around m ean values 
generated from a sam ple of the general populat ion.  The weights represent  
valuat ions of health- related well-being (or ut ilit y) , and are anchored on 1 
( represent ing full-health)  and 0 (represent ing death or health states considered 
to be equivalent  to death) . 
 
There has been increasing discussion in the econom ic lit erature, about  the 
appropriateness of using these general populat ion values within technology 
appraisal (Brazier et  al. ,   2005) .  I t  is argued, by som e, that  pat ient  values are 
bet ter est im ates of health- related well-being as pat ients have first  hand 
experience of the health state.  Describing a part icular health state, then asking a 
m em ber of the general public to place a value on it ,  is potent ially flawed by the 
lim itat ions of the descript ive system  used to describe the health state and the 
ability of a m em ber of public to im agine what it  is like to be in that  health state.  
Given these problems, it  is lit t le wonder that  large differences between pat ient  
and public values are observed. 
 
Despite these problem s, the use of general populat ion values cont inue to 
dom inate technology appraisals, although the reasons for this tend to focus on 
the potent ial disadvantages of using pat ient  values.  One group of influent ial 
economists argued that  society should adopt  a ‘veil of ignorance’ when choosing 
health state values to purposely avoid the influence of self interest  (Gold et al. ,  
1996) .  Such self interest , it  has been argued, can lead to st rategic behaviour 
when collect ing health values.  Another problem avoided by the use of populat ion 
values is that  som e aspects of pat ient  values may want  to be excluded from  our 
valuat ion of health outcom es.  Adaptat ion, it  is argued can lead to pat ients being 
sat isfied with their dim inished funct ioning, thus leading to higher than expected 
values, and conversely, lower than expected gains from  t reatment . 
 
The disquiet  around the problems with general populat ion values has led to calls 
for using bet ter inform ed general populat ion values.  Such values are seen as 
having the benefit s of m aintaining a social perspect ive, with fewer of the 
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problems associated with their lack of experient ial knowledge.  Whilst  there is an 
increasing am ount  of work around pat ient  values, and their  role within technology 
appraisal, the cost -effect iveness decision rule that  lies at  the heart  of funding 
decisions has rem ained unquest ioned. 
 
 
The current  cost - effect iveness rule 
 
The cost -effect iveness rule used rout inely in technology appraisal is that  for any 
given m onetary value placed on health (or a QALY) , the recomm ended t reatm ent 
for funding is ident ified as that  with the highest  incremental cost -effect iveness 
rat io ( I CER)  that  falls beneath this threshold value1.  
 
This cost -effect iveness rule can be illust rated using Table 1.  ‘Do nothing’ 
represents a situat ion where no act ive therapy is given to the pat ient , t reatm ents 
‘A’, ‘B’ and ‘C’ are new, m ore expensive therapies.  Using the current  decision 
rule, and a threshold value of £30 000 per QALY, we see that  t reatm ent A is 
deem ed the m ost cost -effect ive, and is therefore recomm ended for pat ients with 
the condit ion. 
 
 
Table 1 :  Cost -effect iveness of four hypothet ical t reatm ent  choices 
 
Treatm ent  Cost  QALYs I ncrem ental cost-
effect iveness rat io 
relat ive to DN 
I ncrem ental cost-
effect iveness rat io 
relat ive to next  
best  opt ion 
C 100 000 5.5 39 600 100 000 
A 50 000 5.0 24 500 20 000 
B 20 000 3.5 38 000 38 000 




However, the current  decision rule is const ructed around a technical quest ion, 
nam ely, ‘which is the m ost  cost -effect ive t reatment?’, when the quest ion that  
should be asked is ‘which t reatments should be offered to the pat ient?’.  Under 
the current  rule, som e pat ient  choice rem ains as a pat ient  can not  be forced to 
accept  the therapy deem ed m ost -cost -effect ive;  they actually have the choice of 
‘Do nothing’ and ‘A’.  However, some pat ients may prefer t reatm ent  ‘B’ over 
t reatm ent ‘A’, but  are not  allowed this under the decision rule, even though it  is 
expected to cost  less than A.2 
 
This situat ion is produced because m ean ex post  general populat ion values and 
ex ante individual pat ient  values rank the t reatm ents different ly;  populat ion 
values suggest  that  t reatm ent ‘A’ is preferred, whilst  pat ient  values suggest  that  
t reatm ent ‘B’ is preferred.  I t  also produces an inconsistency with respect  to the 
im plied pat ient  choice within the current  decision rule;  pat ients are able to choose 
one t reatm ent which costs less but  is deem ed less effect ive based on mean 
general populat ion values ( i.e. ‘Do nothing’) , but  not  another ( i.e. ‘B’) . 
 
                                               
1 Although the decision rule should relate to the increment relative to the next best option, the rule is 
frequently operationalised with the increment relating to ‘do nothing’ or ‘current treatment’. 
2 The position of treatment A is recognised by economists in terms of ‘extended dominance’ 
(Weinstein 1990), a concept that is used to rule out the treatment from further consideration as a 
potentially cost-effective treatment. 
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The case of osteoporosis 
 
Nat ional I nst itute for Clinical Excellence (NI CE)  Technology Appraisal 87 (NI CE 
2005)  sets out  recomm endat ions for the use of bisphosphonates, select ive 
oest rogen receptor m odulators and parathyroid horm one for the secondary 
prevent ion of osteoporot ic fragilit y in postm enopausal wom en.  The cost -
effect iveness analysis for this appraisal is com plex with alternat ive figures 
produced for alternat ive evidence bases, and pat ient  populat ions described in 
terms of age and bone m ineral density.  A summ ary of the result s are given in 
Table 2, which includes a single bisphosphonate (as opposed to the three which 
were assessed) , raloxifene, oestrogen, and teriparat ide. 
 
I n sum m ary, the guidance recomm ended bisphosphonates as the preferred 
t reatm ent , with the opt ion for using raloxifene if bisphosphonates were 
cont raindicated, produced an unsat isfactory response or if pat ients were 
physically unable to com ply with the st r ict  direct ions for taking bisphosphonate 
m edicat ions (NI CE 2005) .  The use of bisphosphonates entails fast ing and 
ingest ion of medicat ion at  least  30 minutes before breakfast  and rem ain standing 
for 30 m inutes after taking the tablet . 
 
 
Table 2 :  Cost -effect iveness of t reatm ents for  the secondary prevent ion 
of osteoporot ic fragility in postm enopausal w om en at  7 0  years of age*  
 
Treatm ent  Cost  QALYs I ncrem ental cost-
effect iveness rat io 
relat ive to DN* *  
I ncrem ental cost-
effect iveness rat io 
relat ive to next  best  
opt ion* * *  
Teriparat ide 7 172 5.54 134 728 -1 257 781 
Raloxifene 3 147 5.55 29 993 -24 371 
Alendronate 2 818 5.56 16 934 8 934 
Oest rogen 2 383 5.51 69 585 69 585 
Do nothing 1 868 5.50   
 
*  Some t reatm ents and analyt ic scenarios have been excluded from  the full table 
presented by Stevenson and colleagues (2005)  for sim plicity. 
* *  Figures taken from  report .  ICERs based on m odel est im ates, whilst  costs and 
QALYs are rounded.  
* * *  Figures calculated from  table, as they are not  available from  the report .  ICER for 
Oest rogen kept  the same as in previous column for consistency. 
 
 
The NI CE guidance did not  allow pat ients the choice of taking oest rogen, even 
though it  is possible that  they would consider the lifestyle rest rict ions associated 
with alendronate as being disrupt ive to the extent  that  oestrogen was considered 
preferable.  I n such a situat ion, the pat ient  would be offered a t reatm ent that  
they considered to be worse and m ore expensive (alendronate) .  Only if they 
were “physically unable”  to follow the t reatm ent direct ions would they be allowed 
to even consider another t reatm ent choice ( raloxifene) , and then not  oest rogen. 
 
Whilst  there are som e added com plexit ies with this technology appraisal, due to 
other uncertaint ies relat ing to oest rogen and raloxifene, the exam ple serves to 
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highlight  the potent ial for cheaper, pat ient -preferred t reatm ent opt ions to exist  in 
real life and to be om it ted from  t reatm ent  opt ions by reimbursement  authorit ies. 
 
 
A pat ient - based cost -effect iveness rule 
 
Clearly, the current  decision rule is capable of producing uncom fortable scenarios 
that  are generated by differences between m ean general populat ion values and 
individual pat ient  values.  Som e work has been undertaken to assess the 
feasibilit y of calculat ing pat ient  specific I CERs (Sculpher 1998) .  However, this 
approach requires the elicit at ion of ex ante health states from  all pat ients 
requir ing t reatm ent  so as to calculate individual expected QALYs, which is a 
daunt ing prospect . 
 
A part ial resolut ion of the problem  is to reformulate the current  decision rule so 
that  it  bet ter reflects the key quest ion of ‘which t reatm ents should be offered to 
the pat ient?’.  The proposal raised here, is to allow pat ients to have a choice over 
the m ost  cost -effect ive therapy (as adjudged by m ean general populat ion 
values) , those t reatm ents that  are less cost ly than the cost -effect ive therapy, and 
‘do nothing’.  Pat ients would not  be given the choice of therapies that  are m ore 
expensive and m ore cost ly than the m ost cost -effect ive therapy ( for exam ple, ‘C’ 
in Table 1) . 
 
This reflects a two-part  decision process;  the ident ificat ion of the m ost  cost -
effect ive therapy using m ean general populat ion values ( i.e. the current  rule) , 
then relat ive to that , the ident ificat ion of those t reatments that  are cheaper than 
the m ost  cost -effect ive therapy. 
 
Under this pat ient -based cost -effect iveness rule, if a pat ient  prefers a t reatm ent  
such as ‘B’ in Table 1 (or oestrogen in Table 2) , they should be able to choose it .   
I n effect  they have adjudged that  their  well-being will be greater under ‘B’ than 
for ‘A’ and the mean costs are lower.  I n other words, when assessing the 
pat ient -preference I CER, ‘B’ dominates.  Treatment ‘C’ would not  be offered even 
if t he pat ient  chose it ,  as the increased well-being needs to be t raded-off with 
increased costs. 
 
One further issue is worth considerat ion.  I t  is possible that  a form of adverse 
select ion could exist , whereby those who choose B are expected to have costs 
m uch greater than the m ean populat ion values ( i.e. £20 000) .  This would result  
in higher pat ient  well being but  potent ially very high costs.  This can be guarded 
against  by using sub-group analyses to see if they belong to a pat ient  group who 
are expected to have higher costs that  A. 
 
The pat ient  based cost -effect iveness rule then becom es:  you offer the pat ient  the 
choice of the t reatm ent  that  has the highest  I CER under the threshold, or a lower 
cost  t reatm ent  if and only if  t hey belong to a pat ient  sub-group that  has lower 




Potent ia l problem s 
 
Two issues are worth further considerat ion.  First ly, the nature of the cost  savings 
produced by the proposed rule, as these are not  certain.  Secondly, the ‘validit y’ 
of a rule which offers a pragm at ic solut ion with no theoret ical base. 
 
Nature of the cost  savings 
 
The pat ient -based cost -effect iveness rule offers the possibilit y of pat ients 
choosing a cheaper t reatm ent  ( ‘B’)  than that  recom m ended using the current  
approach ( ‘A’) .  However, it  is possible that  without  this choice, som e pat ients 
would have chosen ‘do nothing’.  I n such circumstances, the offer of an 
alternat ive t reatm ent  ( ‘B’)  raises the possibility of increased costs.  Consequent ly, 
whether the proposed rule is cost -saving or cost- increasing at  the populat ion 
level, is an em pir ical quest ion. 
 
Theoret ical validity of the rule 
 
Whilst  the proposed rule has been described in the context  of cost -effect iveness 
decisions, and taps into not ions of a pat ient -preference I CER, it  does not  have the 
theoret ical base of cost -effect iveness analysis.  I t  is a pragm at ic solut ion, that  
m ixes together societal and pat ient  perspect ives.  I t  could also be argued that  the 
wider choice it  provides m oves away from the not ion of the public provision of 
health care, to a social insurance m odel where pat ients have a right  to choose 
from  a m enu of approved t reatm ents. 
 
So, does the lack of a theoret ical foundat ion and the m ixing up different  
perspect ives within a decision rule invalidate the rule?  I t  is clear that  the NHS 
does not  operate a single all-encom passing evaluat ive fram ework.  Whilst  ext ra-
welfarism  is used by m any health economists to just ify the predom inant  
evaluat ive fram ework used by them selves, the NHS uses a range of decision 
m aking cr iteria from a mixture of sources;  theoret ical, pragm at ic and polit ical. 
 
These different  views are recognised by Drummond and colleagues (Drum m ond 
et  al, 2005)  who cont rast  the pragm at ic ‘decision-m aking approach’ with the 
theoret ical approaches of welfarism  and ext ra-welfarism .  The rule forwarded in 
this paper is clearly pragm at ic, and from a decision-m aking perspect ive, I  would 
argue that  it s desirabilit y can be evaluated.  The decision m aker needs to 
evaluate whether the benefit s the rule confers in terms of greater choice and 
greater health benefits as evaluated by the pat ient , are worth the potent ial ext ra 
cost  and reduced health benefit s as evaluated by a populat ion tar iff.  
 
 
Sum m ary 
 
Cost -effect iveness rules have developed to answer a technical quest ion, without  
due regard for pat ient  choice.  Am ending this rule allows greater choice for the 
pat ient  without  necessarily increasing the program m e cost .  However, using the 
m et ric of general populat ion values this alternat ive decision rule reduces health 
gains.  This loss of ex post  society-valued health gain must  be balanced against  
the increase in pat ient  choice and ex ante pat ient -valued health gain.  Whether 
society is willing to bear the potent ial extra cost  for these gains becomes the 
cent ral quest ion. 
 
I t  should be noted that  when funding decisions are operat ionalised, health care 
professionals reinterpret  them  to allow pat ient  choices of this nature.  I t  is also 
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possible that  such circum stances are rare, and m ade rarer st ill by the use of non-
cost  effect iveness inform at ion in the decision process to account  for pat ient  
concerns. Consequent ly, the adopt ion of this pat ient -based cost -effect iveness rule 
m ay not  alter m any decisions com pared to the current  approach. Even if this 
were the case, it  would represent  a sm all but  profound shift  in the way in which 
evaluat ions are conceptualised, by recognising the cent ral im portance of pat ient  
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